Monday, 6 April 2020

Coma Diagnosis and Treatment Market Strategies And Competitive Analysis, Forecast Till 2023

Coma Diagnosis & Treatment Market Research Report: By Types (Toxic-Metabolic Encephalopathy, Anoxic Brain Injury), Diagnosis (Physical Examination, Brain Scans) Treatment (Medical Treatment), End User (Hospitals & Clinics) - Global Forecast till 2023
Market Scenario
Coma refers to a state of unconsciousness in which a patient remains unresponsive to anything around them for a prolonged period of time. Depending on the severity of the coma, patient may require life-saving resuscitative measures and once the patient is medically stable, treatments can be used to treat original problem that is causing the coma.
There is no particular treatment that can cause someone to come out of a coma and treatments can prevent further physical and neurological damage. However depending on the cause of a coma, patient who are continuosly in this state for more than one year are extremely unlikely to awaken.
Increasing prevalence of neurological disorders, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the Coma Diagnosis and Treatment Market Size. Moreover, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases will fuel the market growth during the forecast period
Over the last decade, the number of hospitals has increased to a great extent, which has influenced the growth of the market positively. Moreover, increasing demand for better treatment and changing reimbursement policies have fueled the market growth.
According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.
However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.
The global coma diagnosis & treatment market is expected to grow at a CAGR of ~7.1% during the forecast period 2017-2023. 
Key Players
  • GE Healthcare (U.S.)
  • Siemens Healthcare(U.S.)
  • Philips Healthcare (U.S.)
  • Carestream Health (U.S.)
  • Electrical Geodesics Inc. (U.S.)
  • Masimo Corporation (U.S.)
  • Hologic (U.S.)
  • Shimadzu Corporation (Japan)
  • Toshiba Medical Systems Corporation (Japan)
  • Fujifilm Holdings (Japan)
  • Nihon Kohden Corporation (Japan)
  • Esaote (Italy)
Regional Analysis
Asia Pacific is the fastest growing coma diagnosis & treatment market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.  
The Americas dominate the global coma diagnosis & treatment market owing to well-developed technology, increasing patient population for brain disorder, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.
On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Europe holds the second position in the global coma diagnosis & treatment market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.     
Segmentations
The global coma diagnosis & treatment market is segmented on the basis of types, diagnosis, treatment, and end user.
On the basis of diagnosis it is segmented into physical examination, blood test, brain scans, and others. Brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG).
On the basis of the type, it is segmented into toxic- metabolic encephalopathy, anoxic brain injury, persistent vegetative state, locked-in syndrome, and brain death.  
On the basis of treatment it is segmented into medical treatment, and others.
On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.

Connective Tissue Disease Market Opportunities, Drivers, Manufacturers, Analysis And Forecasts Till 2023

Connective Tissue Disease Market Research Report information: Diagnosis (X-ray Examination, Antinuclear Antibody Test, Treatment (Non-Steroidal Anti-Inflammatory, Cortisone/Steroids, Antimalarial, Cytotoxic Drugs), End User - Global forecast till 2023
Connective tissues are a group of cellular congregations that provide support and structure to the human body. Connective tissue disease is a group of disorders which involves these protein rich tissues. Protein rich tissues play an important role of supporting organs and other parts of the body. Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels. More than 200 disorders affect the connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.
Developments in the treatment of connective tissue diseases (CTDs) have been improved considerably, and the global connective tissue disease treatment market is slated to grow at a promising CAGR of 11.5% over the forecast period of 2017-2023. The cause of the disease is unknown and there's no cure for connective tissue disease yet, but medications are present to manage the signs and symptoms. CTDs include a large number of disorders which can affect different organs of the body. There is broad variability in disorders among patient suffering from CTDs.
It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.
A significant increase in the research and development efforts to find treatment and cure for CTDs have aided the growth of the market. Various therapy trials are underway which have been able to identify promising novel approaches to treat CTDs and are expected to boost the growth of the market. Rising prevalence of CTDs across the globe, especially in women has propelled the growth of the market. Additionally, support from governments across the world along with funds for R&D from the private industry is also a key driver of the growth of the market. With the increase in awareness and acceptance among the general population about connective tissue diseases, the diagnosed and drug-treated population will increase which will positively impact the market. Rising expenditure on healthcare, high unmet medical needs of the current treatment and growing prevalence of CTDs in Asia and Africa are expected to promote the growth of the market.  However, the growth of the market might be hindered by lack of a knowledgeable workforce, inadequate research and development infrastructure, lack of funds in middle and low-income countries.
Key Players
Some of key the players in the market are
  • Abbott Laboratories
  • Bayer AG
  • Hoffmann-La Roche Ltd
  • Pfizer
  • AutoImmune Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • Biogen
  • LUPIN
Segmentation
The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.
On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others
On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.
Regional Analysis
The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.
Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.
Asia Pacific is the fastest growing market connective tissue disease, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities. 

Augmented Bone Graft Market Size, Share Analysis, Strategies, Revenue And Forecasts To 2023

Augmented Bone Graft Market Research Report by product (Allografts, Bone Grafts Substitutes, Cell-based Matrices), application (Craniomaxillofacial, Dental, Foot & Ankle, Joint Reconstruction, Long Bone, Spinal Fusion), end user– Global forecast till 2023
According to the British Editorial Society of Bone & Joint Surgery, bone is the second most common transplanted tissue after blood with an estimated 2.2 million grafting procedures worldwide annually as recorded in 2015. This development has been fuelled by the increasing cases of fractures and accidents around the world.
The Global Augmented Bone Graft Market is expected to grow at a CAGR of approximately 7.8% during the forecast period 2017-2023.
Augment Bone Graft is a combination drug/device product used for repairing the bone and reviving its regenerative properties. It is used as an alternative to autograft in arthrodesis of the ankle or hindfoot indicating the need for supplemental graft material. The use of augment bone graft eliminates the need for a second surgery to harvest autologous bone, thereby avoiding donor site morbidity. According to the National Health Interview Survey, in 2012, around 126 million adults were affected by this disease in the U.S. According to the Labor Force Survey (LFS), about 553,000 cases were registered for all work-related musculoskeletal disorder out of the total of 1,243,000 cases.
Allografts and bovine-derived bone graft products dominate the augmented bone graft market. These materials have variations in particle size which is their main drawback. The recent technological trend is to replace these natural materials with alloplastic bone grafts such as ceramics and polymers as they can be manufactured to the precise size and characteristics.
There has been increasing acceptance of bone grafting procedures which drives the market for augmented bone graft products. Many healthcare professionals have started using these bone grafts, especially in tertiary care centers and specialty hospitals which may promote and increase the demand for augmented bone graft. These bone graft works in a unique way to stimulate three key processes of early bone healing.
Various other factors such as, increasing advancement in technology, and rising adoption rate of new technology continuously contribute to the growth of this market. Despite these developments, high cost of surgeries and ethical issues related with bone grafting procedures may hamper the growth of the market. For instance, a study conducted by BMC Medical Ethics states that in a sample of 100 patients, about 20% of the patients refuse to accept allografts for their grafting surgery.
Additionally, stringent regulations obstruct the growth of augmented bone grafts market size and inadequate reimbursement policies for bone grafting also hampers the growth of global bone grafts market. Rapid product launches and increasing mergers and acquisitions between bone graft systems manufacturing companies are some of the major trends in the global bone grafts market.
The Key Players
  • Zimmer Holdings, Inc.
  • BioMimetic Therapeutics LLC
  • Wright Medical Technology, Inc.
  • Stryker Corporation, Smith & Nephew Plc
  • RTI Surgical, Inc.,
  • Olympus Biotech Corporation
  • NuVasive, Inc.
  • NovaBone Products LLC
  • Medtronic, Inc.
  • LifeNet Health, Inc.
  • Integra LifeSciences Holdings Corporation
  • Exactech, Inc.
  • DePuy Spine, Inc.
  • Synthes Inc.
  • DePuy Synthes Companies
  • Biomet, Inc.
Segmentation
The Augmented Bone Graft is segmented on the basis of products, application, and end-users.
On the basis of application, the market is segmented into the Craniomaxillofacial, Dental, Foot & Ankle, Joint Reconstruction, Long Bone, and Spinal Fusion
On the basis of product, the market is segmented into the Allografts, Bone Grafts Substitutes, and Cell-based Matrices. The Allografts segment is further sub divided into Machined Allografts and Demineralized Bone Matrix. The Bone Grafts Substitutes is also sub categorized as Bone Morphogenic Proteins (BMP) and Synthetic Bone Grafts.
On the basis of end-user, the market is segmented into hospitals, clinics, ambulatory surgical centers and others.
Regional Analysis
The Global Augmented Bone Graft Market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America dominated the global augmented bone graft market owing to the increasing healthcare expenditure in North America since 2016. Canadian healthcare specifically was stressed by an advancing demographic move. The increase of insurance coverage because of health care reform (Affordable Care Act) in the United States additionally prompted an expansion in health care spending. In 2016, healthcare organizations found liberation from a special tax on medical devices (Medical Device Excise Tax). The United States Congress put off the tax for a long two years in 2015.
For Europe, the healthcare spending has expanded slightly in Germany. Neverthelss, the orthopedic biologics market including the bone graft substitute market has been determined by solid strong competition and price pressure. While volume of sales and the scope of new treatment techniques are on the ascent, net revenues in the German market are declining. Western Europe continues to see a need to save money on healthcare because of a slight drop in financial growth and obstinate economic pressure.
Healthcare spending in Asia expanded in 2016 due to an extension of state health care programs and the increasing affluence of the population. India, in specific, saw an expansion in spending due to a government resolution to enhance healthcare services.
Furthermore in the Middle East & Africa the spending for healthcare was also increased. This was essentially because of elections in a few nations, (for example, Ghana, Niger, Uganda, Zambia and Somalia), healthcare growth and population growth. Awareness for medicinal technology likewise expanded extraordinarily. Due to of low local production, the region is dependent on imported medicinal products. The import standard in numerous nations is 80% to 90%.

Acute Care EHR Market Opportunities, Drivers, Manufacturers, Analysis And Forecasts Till 2023

Acute Care Electronic Health Recorder (EHR) Market Research Report- Information By Deployment (On-Premise Based, Cloud-Based), By Application (Personal Care, Pharmaceuticals), and By End User (Hospitals, Ambulatory Care) - Global Forecast till 2023
Acute care EHR is different from its traditional counterparts. The acute care EHR allows healthcare professionals to collect, preserve and access vital patient clinical data in acute care and ambulatory care settings. Market Research Future (MRFR) perceives the global acute care EHR market to register a CAGR of 7% over the forecast period of 2017-2023.
The global acute care EHR market growth driven by the surging incidences of chronic diseases on a global scale. In recent years, the prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disease have been on the rise which has consequently raised the number of healthcare institutions. Growth in a number of hospitals and other medical centers have created massive demand for management of patient data which boosts the growth of the global acute care EHR market. The rise in global geriatric population is also a contributing factor to the growth of the global acute care EHR market. The aged population who are more susceptible to suffer from chronic diseases have induced high demand for remote monitoring of geriatric patient data. Factors such as development in healthcare IT, technological advancements and expanding expenditure on healthcare act as a plus for the growth of the market. On the contrary, the growth of the global acute care EHR market might be restrained by high costs associated with acute care EHR solutions which might limit the growth of the market in price-sensitive market. Furthermore, towering costs of healthcare devices and treatments are also likely to hinder market growth.
Competitive Landscape
The noteworthy players in the global acute care EHR market include Epic Systems Corporation (U.S.), Evident (CPSI) (U.S.), eClinicalWorks (U.S.), Medhost (U.S.), Athenahealth (RazorInsights) (U.S.), IBM (U.S.), Vitera Healthcare Solutions (U.S.), Meditech (U.S.), McKesson Corporation (U.S.), Allscript (U.S.), Cerner Corporation (Siemens) (U.S.), Healthland (U.S.), and General Electric Company (U.S.).
Segmentation
The global acute care EHR market has been segmented based on deployment, application, and end user. 
By deployment, the global acute care EHR market has been segmented into On-Premises based and Web-based.
By application, the global acute care EHR market has been segmented into personal care, pharmaceuticals, and others.
By end user, the global acute care EHR market has been segmented into hospital, ambulatory care, and others.
Regional Analysis
The Americas dominate the global acute care EHR market owing to the increasing number of hospitals ambulatory centers, presence of huge patient population and well developed technology. The hospital and clinics are able to afford the cost of the devices as these are funded by several sources: the public sector, charities, health insurance companies, health organizations of all kinds, etc. Additionally, the people in this region are able to afford high cost of treatment on account of higher per capita income in this region. Rapidly increasing patient population, governments have started supporting the manufacturers for the development of new and better devices which has driven the growth of the market. Moreover, well developed technology, high healthcare expenditure, and huge geriatric population have fuelled the growth of the market in this region.
Asia Pacific is the fastest growing acute care EHR market owing to the increasing number of patients suffering from chronic diseases and rapidly increasing number of hospitals & clinics. Additionally, rapidly growing economies and increasing healthcare expenditure will fuel the growth of the market. On the other hand, the Middle East & Africa hold the least share of the market owing to less availability of funds, limited availability of medical facilities, and poor political conditions in Africa.
Europe commands the second largest market for acute care EHR which is followed by Asia Pacific. Availability of funds, strong government support, and increasing need for the better management devices & platform drive the growth of the market in Europe. Western Europe holds a major share of the market due to the presence of well developed economies. U.K, Germany and France are the major contributors of the market.
Industry Updates
  • In November 2018, ResMed, a company that specializes in connected devices and remote monitoring for sleep apnea and respiratory illnesses announced the acquisition of MatrixCare’s post-acute care EHR solution for USD 750 million.
  • In December 2018, Allscripts, a provider of healthcare solutions, announced selling of its stake in post-acute care EHR vendor Netsmart to TA Associates and GI Partners, both private equity firms for a total amount of USD 525 million.

Retropharyngeal Abscess Market Shares Analysis, Key Development Strategies And Forecasts Till 2023

Market HighlightsRetropharyngeal abscess is a serious infection deep in the neck and generally occurs in children under age eight, though it can also affect adults. The symptoms include difficulty in breathing and swallowing, pain, severe cough and throat pain, neck stiffness and spasms and others. If left untreated, retropharyngeal abscess infection can result in septic shock, organ failure and death. Retropharyngeal abscess recurs in an estimated 1 to 5% of patients and such patients are 40 to 50% more likely to die due to abscess-related complications.
The market drivers include rise in demand due to growing young and immune-compromised population, increasing screening, and others. The market restraints are the complications such as risk of bleeding, pain, especially during surgery, high cost of treatment, poor healthcare penetration and others.
Development of antibiotics resistant bacteria is the single most unmet need of the market. Product development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to development of selective gram negative antibiotics. Market development is another strategy for as there is a large unmet need in the developing regions such as India and China. Cost of the product will be a decisive factor in the developing regions such as Asia Pacific and especially Africa.
Global Market Players
Some of the key players profiled in the report are Merck KGaA, Johnson & Johnson, AstraZeneca plc, Sanofi S.A., Pfizer, Mylan N.V, Novartis AG, Teva pharmaceutical company, GlaxoSmithKline plc, and others.
Regional Analysis
The Americas accounts for a significant market share owing to high expenditure on the health care and greater healthcare penetration especially of the U.S. and Canada. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.
Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry. The development of Methicillin-resistant Staphylococcus aureus (MRSA) especially in the southern regions of Europe such as Spain, Italy etc. stimulates the market.
Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future retropharyngeal abscess market in the region.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development.
Segmentation
The global market has been segmented on the basis of diagnosis, treatment, and end user.
Based on the diagnosis, the market has been segmented as X-rays and computed tomography, blood tests, physical exam and others.
Based on the treatment, the market has been segmented as calcium antibiotics, pain killers, surgical drainage and others.
Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.
Taste the market data and market information presented through more than 50 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Global Retropharyngeal abscess Market” Research Report – Forecast till 2023.

Microbiology Testing Industry Growth, Trends And Forecast Till 2023 By Marketresearchfuture.Com

Global Microbiology Testing Market - Overview
Microbiology testing has emerged as one of the rapidly changing and growing segment of healthcare over the past few years. Microbiology testing deals with the study of microbial germs and their clinical applications for the improvement of health. Microbiology testing is concern with the diagnosis, prevention and treatment of various infectious diseases such as, sexually respiratory infections, urinary tract infections, gastrointestinal infections, sexually transmitted infections, and many others. These diseases can be spread from one person to another, directly or indirectly.
According to a recent study published by the Market Research Future analysts, the global microbiology testing market is growing at a double digit growth rate; mainly due to factors such as technological advancements, rising cases of infectious diseases, surveillance programs for disease control, and rising stringency of standards.  On the other hand, erroneous results produced during the testing, and heavy costs of the tests and instruments have created some obstacles in the growth of this market in all parts of the world.
Global Microbiology Testing Market - Competitive Analysis
There are large number of companies involved in the development of the products, instruments, and test kits for the microbiology testing which are now being used in majority part of the developed countries. Global market for microbiology testing is majorly dominated by Biomérieux SA with more than 40% of market share in 2016.
Major companies are adopting a specific strategy to enter and create unique space in this market. The different strategies includes, product launch, agreement and collaboration, partnership and expansion, joint venture and strategic alliance etc. All major players are focusing on new product development to provide new and innovative solutions to the market.
Biomérieux SA offers a comprehensive range diagnostic solutions which include Microbiology lab instruments, reagents and software. The products of the company is mainly used for diagnosing infectious diseases. In 2016, BioMérieux announced the acquisition of Hyglos. With this acquisition, the company plans to strengthen its position in the market.
Some of the major developments in this segment came from the Roche Diagnostics. In April 2017, the company received FDA clearance for the CINtec Histology test. This test is the only clinically validated p16 biomarker test. The CINtec Histology test will help physicians make informed decisions as to the best course of care for patients with high-grade pre-cancerous cervical disease. Back in 2015, Roche acquired GeneWEAVE to strengthen offerings in microbiology diagnostics.
The global market consist of players such as Alere (US), BD (US), Beckman Coulter, Inc. (US), Biomérieux SA (France), Cepheid (US), F. Hoffmann-La Roche Ltd (Switzerland), and Thermo Fisher Scientific Inc. (US). These are the prominent players at the forefront of competition in the global microbiology testing market and are profiled in MRFR Analysis report.
Global Microbiology Testing Market - Regional Analysis
In 2016, North America and Europe were holding more than half market share of global microbiology testing market. Increasing funding for R&D is major driving force for the market growth. The funding for microbiology testing in US is one of the highest as compared to other countries. Rapid adoption of advanced products and techniques are driving the growth for North America market. Increasing cases of infectious diseases are promoting the research related activities in this region. Independent laboratories are dominating the North America market by adopting new technologies and trends.
European market is second highest revenue generator after North America. Europe microbiology testing market has benefited by the presence of some major players in this region. Moreover, increasing innovation and changing laboratory practices are driving the growth for Europe microbiology testing market. Microbiology testing have huge and increasing demand not only in developed countries but also in developing countries like China, India, and Spain.
Rising prevalence of respiratory infections are increasing burden on Asia-Pacific healthcare system. Being a large population base, increasing aging population, and increasing use of technology in healthcare, China microbiology testing market is growing at rapid pace. China is expected to grow at a CAGR of 12.8% during the forecast period. The number of independent laboratories are rapidly increasing such as KingMed Diagnostics and Dian Diagnostics. KingMed Diagnostics is largest chain of independent laboratories in china.
The Middle East and Africa microbiology testing market is growing dramatically due increasing prevalence of various infectious diseases like Ebola. This region is carrying greatest burden of infectious disease. Sexually transmitted diseases are also major public health problem in this region. There are some factors are affecting the microbiology testing market in this region such as, limited access to the healthcare facilities, lack of knowledge of new microbiology testing techniques, less funding R&D, limited availability of products etc.

Over-The-Wire Micro-Guide Catheter Market Professional Overview 2019-2023 With Major Vendors Size, Shares And Worldwide Demand

Market Highlights
Over-the-wire Micro Guide Catheter (OTW Micro Guide Catheter) is a thin tubular Medical device inserted into the body for diagnosis or treatments of diseases like cardiovascular, neurovascular, and urology. Specially designed to ease complex procedures, OTW Micro Guide Catheter combining excellent cross-ability and optimal guide-wire support, can effectively treat challenging cases involving tortuous vessels, CTO (chronic total occlusions), bifurcations, and highly stenosed and calcified lesions, giving the high success rate.
OTW Catheters are widely used in cardiovascular applications such as peripheral and coronary interventions and neurovascular interventional applications. The high success rate associated with the use of these catheters further augments its uptake and demand, resultantly driving its market growth.
According to Market Research Future (MRFR), the global Over-the-wire Micro Guide Catheters market is expected to grow at a CAGR of 9.37% during the forecast period (2018–2023).
According to reports published by the Centers for Disease Control and Prevention, the coronary heart disease is the most common type of heart diseases that accounted for the death of about 366,000 people in 2015.
Over-the-wire catheters comparatively make a better choice to treat a brain aneurysm than the rapid exchange catheters owing to their capabilities of extra pushing to enter stenose vessels, and additional support that they provide.
The increasing occurrences of coronary heart diseases, neurovascular diseases, hypertension, and other metabolic disorders, raising awareness for health, advancement in technologies, good healthcare infrastructure, and favorable reimbursement policies are fueling the market growth. 
Regional Analysis
The global over-the-wire micro guide catheters market is segmented into four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas is the global market leader for over-the-wire Micro-guide catheters. As per the study published in the Surgical Neurology International in 2017, it was found that more than 3% population of the United States equivalent to nearly 10 million individuals have a brain aneurysm. North America commands for the major share of the market whereas; South America show the fastest growth of the market due to the presence of boundless growth opportunities.
Europe OTW Micro Guide Catheter market holds the second position, globally. This is primarily attributable to the increasing prevalence of obesity as well as the increased incidence rate of hypertension and diabetes, which in turn is escalating cardiovascular traumas and cardiac arrest. Each year 15% of deaths in Europe occur due to cardiovascular diseases claims a study conducted by European Society of Cardiology.
The Asia Pacific region is the fastest growing market for the over-the-wire micro guide catheters. The region presents significant growth opportunities for market players as local policy makers continue to restructure the policy framework for the healthcare sector.
Global OTW Micro Guide Catheter Market: Segmentation
The global over-the-wire micro guide catheters market is segmented on the basis of applications and end-users. On the basis of applications, it is segmented into cardiovascular and neurovascular. By the cardiovascular, it is segmented into angiography, angioplasty, peripheral stenting, and others. On the basis of the neurovascular, it is segmented into intracranial aneurysms, percutaneous neurointerventional procedures, and others. Based on end-user the market is segmented into hospitals & clinics, ambulatory surgical centers, research & academic institutes, and others.  
Major Players in the Over-the-wire Micro Guide Catheters Market
Enki – Microtubes, Cardinal Health, DePuy Synthes, Koninklijke Philips N.V, Penumbra Inc., Terumo Europe N.V., Integer Holdings Corporation, Merit Medical Systems Inc., Teleflex Incorporated, Cook Medical, Boston Scientific Corporation, Asahi Intecc Company Limited, and Medtronic plc.